Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in china: A multis-center case-controlled study of 1,153 subjects

BioScience Trends

Volumn 8, Issue 5, 2014, Pages 266-273

  Song, Peipei ^a   Feng, Xiaobin ^b   Inagaki, Yoshinori ^a   Song, Tianqiang ^c   Zhang, Keming ^d   Wang, Zhigang ^a   Zheng, Shuguo ^b   Ma, Kuansheng ^b   Li, Qiang ^c   Kong, Dalu ^c   Wu, Qiang ^c   Zhang, Ti ^c   Zhao, Xin ^d   Hasegawa, Kiyoshi ^a   Sugawara, Yasuhiko ^a   Kokudo, Norihiro ^a   Tang, Wei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d BEIJING 302 HOSPITAL   (China)

Author keywords

Alpha fetoprotein (AFP); Des carboxy prothrombin (DCP); Sensitivity; Serum biomarker; Specificity

Indexed keywords

HEPATITIS B VIRUS;

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHILD; CHINA; CLINICAL TRIAL; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHILD; CHINA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84909595772     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2014.01116     Document Type: Article

References (33)

1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_ sheets_cancer.aspx (accessed September 8, 2014).
2. Asia - Pacific Working Partyon Prevention of Hepatocellular C. Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. J Gastroenterol Hepatol. 2010; 25:657-663.
3. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J Epidemiol. 2011; 21:401-416.
4. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009; 24:346-353.
5. Song PP, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: Facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013; 2:227-231.
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130:417-422.
7. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127 (Suppl 1):S108-S112.
8. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005; 9:235-251, vi.
9. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 1989; 64:2117-2120.
10. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am J Gastroenterol. 2006; 101:513-523.
11. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review. Hepatol Int. 2008; 2:17-30.
12. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137:110-118.
13. Sassa T, Kumada T, Nakano S, Uematsu T. Clinical utility of simultaneous measurement of serum highsensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1999; 11:1387-1392.
14. Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, Yutani S, Nagamatsu H, Matsugaki S, Yamasaki S, Tanikawa K, Sata M. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alphafetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000; 7:249-256.
15. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23:1541-1548.
16. Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alphafetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves. Tumour Biol. 1992; 13:316-323.
17. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: A consensus-based practice guideline. Oncology. 2010;78 (Suppl 1):78-86.
18. Song PP, Gao JJ, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. Liver Cancer. 2013; 2:31-39.
19. Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J (Engl). 2002; 115:42-45.
20. Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003; 88:1878-1882.
21. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006; 101:2038-2043.
22. Zhang C, Zhong Y, Guo L. Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. Biosci Trends. 2013; 7:7-12.
23. Amarapurkar D, Han KH, Chan HL, Ueno Y, Asia-Pacific Working Party on Prevention of Hepatocellular C. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol. 2009; 24:955-961.24
24. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907-1917.
25. Forner A, Bruix J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 2012; 13:750-751.
26. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. Liver Int. 2012; 32:1053-1063.
27. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310:1427-1431.
28. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37:1114-1121.
29. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000; 95:1036-1040.
30. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci. 1991; 36:1787-1792.
31. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1995; 1:249-255.
32. Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci. 1993; 38:2170-2176.
33. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review. Hepatology. 1993; 18:990-997.